论文部分内容阅读
背景与目的树突状细胞(DC)为基础的免疫治疗是肿瘤治疗的新领域,对部分恶性肿瘤有较好的疗效。本研究的目的是应用癌胚抗原(CEA)致敏的DC治疗晚期非小细胞肺癌(NSCLC),观察其临床应用方法、毒副反应和剂量效应。方法选择CEA高表达的肺癌患者,体外培养外周血单个核细胞来源的DC及CIK,CEA多肽于培养的第5天加入培养液以致敏未成熟DC。将DC和CIK细胞静脉回输患者,观察回输后的疗效和毒副反应。结果共22例晚期NSCLC患者接受了DC治疗,回输DC数量为2.5×106~9.6×107,平均5.03×106;回输CIK细胞数量为3.4×108~46×108。治疗后CD3、CD8、NK、IFN-γ明显升高(P<0.05)。全组1年生存率为68.2%(15/22)。主要毒副反应为发热和皮疹。结论DC生物免疫治疗具有较好的耐受性和安全性。
Background and objective Dendritic cell (DC) -based immunotherapy is a new field of cancer treatment and has a good effect on some malignant tumors. The aim of this study was to investigate the clinical application, side effects and dose effects of carcinoembryonic antigen (CEA) -sensitized DC in the treatment of advanced non-small cell lung cancer (NSCLC). Methods Lung cancer patients with high expression of CEA were selected. DC and CIK derived from peripheral blood mononuclear cells were cultured in vitro. Culture medium was added on day 5 of culture to sensitize immature DCs. The DC and CIK cells were intravenously transfused into the patients and the efficacy and adverse reactions after the infusion were observed. Results A total of 22 patients with advanced NSCLC underwent DC. The number of DCs transfused was 2.5 × 106 ~ 9.6 × 107 with an average of 5.03 × 106. The number of CIK cells transfused was 3.4 × 108 ~ 46 × 108. After treatment, CD3, CD8, NK and IFN-γwere significantly increased (P <0.05). The 1-year overall survival rate was 68.2% (15/22). The main side effects are fever and rash. Conclusion DC biological immunotherapy has good tolerance and safety.